Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions.
Natural history studies have shown that peritoneal carcinomatosis is uniformly fatal, with a median survival in the range of approximately 6 months. For more than a decade, a handful of centers have pursued aggressive intraperitoneal cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy as an alternative approach to this disease. Strict selection criteria, variation in intraperitoneal chemotherapy, and the vagaries of what represents "cytoreductive surgery" make many of our colleagues, particularly those in medical oncology, reticent to refer patients for such an aggressive therapy. This article establishes a conceptual framework for understanding the role of intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal surface malignancy. This procedure continues to make advancements in the oncological community despite formidable challenges. The advancement of centers of excellence and the initiation of further phase II trials will help to define the optimal treatment approach for peritoneal carcinomatosis.
Stewart
John H
JH
Surgical Oncology Service, Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Shen
Perry
P
Levine
Edward A
EA
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000970:Antineoplastic Agents